DAIICHI SANKYO COMPANY, LIMITED
4568 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 中央区日本橋本町三丁目５番１号
- Website:
- https://www.daiichisankyo.co.jp/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Daiichi Sankyo Company, Limited is a leading global pharmaceutical firm based in Japan, dedicated to advancing healthcare through innovative solutions. With a strong emphasis on research and development, the company focuses on creating new drugs and therapies, particularly in the areas of oncology, cardiovascular, and infectious diseases. Daiichi Sankyo is committed to patient-centric approaches, striving to improve the quality of life for patients worldwide. The company also places a significant importance on sustainability and corporate governance, ensuring that its operations align with global health goals and ethical practices. Through its commitment to innovation and compassion, Daiichi Sankyo aims to make a lasting impact on global health.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-17 02:04 |
Prospectus
発行登録書（株券､社債券等）
|
Japanese | 24.8 KB | |
| 2025-07-09 02:32 |
Transaction in Own Shares
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
|
Japanese | 25.2 KB | |
| 2025-06-24 06:02 |
Regulatory News Service
訂正発行登録書
|
Japanese | 8.9 KB | |
| 2025-06-24 05:36 |
Inside Information Statement
臨時報告書
|
Japanese | 25.7 KB | |
| 2025-06-23 08:40 |
Regulatory News Service
訂正発行登録書
|
Japanese | 8.9 KB | |
| 2025-06-23 07:44 |
Inside Information Statement
臨時報告書
|
Japanese | 31.3 KB | |
| 2025-06-20 07:20 |
Internal Control over Financial Reporting
内部統制報告書－第20期(2024/04/01－2025/03/31)
|
Japanese | 23.5 KB | |
| 2025-06-20 07:20 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2025-06-20 07:19 |
Annual Report
有価証券報告書－第20期(2024/04/01－2025/03/31)
|
Japanese | 3.0 MB | |
| 2025-06-09 05:20 |
Transaction in Own Shares
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
|
Japanese | 25.4 KB | |
| 2025-05-12 05:57 |
Transaction in Own Shares
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
|
Japanese | 27.5 KB | |
| 2025-04-09 09:02 |
Regulatory News Service
訂正発行登録書
|
Japanese | 8.9 KB | |
| 2025-04-09 08:37 |
Inside Information Statement
臨時報告書
|
Japanese | 18.4 KB | |
| 2025-04-03 08:06 |
Transaction in Own Shares
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
|
Japanese | 28.4 KB | |
| 2025-03-13 04:31 |
Transaction in Own Shares
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
|
Japanese | 25.7 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Nippon Shinyaku Co.,Ltd. | Japan | 4516 | |
|
Noile-Immune Biotech Inc. | Japan | 4893 | |
|
Novartis AG | Switzerland | NOVN | |
|
Nur Ink Innovations Ltd. | Israel | NURI | |
|
Nxera Pharma Co., Ltd. | Japan | 4565 | |
|
ObsEva SA | Switzerland | OBSN | |
|
ODI Pharma AB | Sweden | ODI | |
|
Oncolys BioPharma Inc. | Japan | 4588 | |
|
OncoTherapy Science, Inc. | Japan | 4564 | |
|
OncoZenge AB | Sweden | ONCOZ |